84 results
Page 2 of 5
8-K
EX-10.1
bsp0r n3wjdt
16 Mar 22
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market
8:30am
424B5
z3srsxzuob6tj472
16 Mar 22
Prospectus supplement for primary offering
8:00am
8-K
EX-10.1
19vcuyfp cp
7 Feb 22
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
4:00pm
8-K
EX-99.1
qfkqs kzizf
10 Jan 22
Other Events
8:00am
8-K
EX-10.1
rhit50vd5ezmqlu
7 Dec 21
Departure of Directors or Certain Officers
6:15am
8-K
EX-10.1
5j2ircol
7 Sep 21
Entry into a Material Definitive Agreement
4:16pm
8-K
EX-99.2
kqfph18 sxhzs0ike
6 May 21
Axcella Reports First Quarter Financial Results and Provides Business Update
7:51am
8-K
EX-10.1
d57dts
3 Mar 21
Axcella Announces Alison D. Schecter, M.D., as President of R&D
5:26pm
S-3
EX-4.4
36v0gq0r
5 Jun 20
Shelf registration
5:02pm
S-3
7jssqa3od
5 Jun 20
Shelf registration
5:02pm